NRD
ABBV icon

Nebula Research & Development’s AbbVie ABBV Stock Holding History

Nebula Research & Development’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,189
Closed -$2.45M – 5
2025
Q2 		$2.45M Sell
13,189
-6,392
-33% -$1.19M 0.21% 146
2025
Q1 		$4.1M Buy
+19,581
New +$3.81M 0.38% 36
2024
Q4 		– Sell
-10,110
Closed -$2M – 873
2024
Q3 		$2M Buy
+10,110
New +$1.89M 0.24% 93
2024
Q1 		– Sell
-3,030
Closed -$470K – 707
2023
Q4 		$470K Buy
+3,030
New +$442K 0.14% 272

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nebula Research & Development's ABBV Position: Q3 2025 in Review

Nebula Research & Development sold out of AbbVie (ABBV) in Q3 2025, closing a stake of 13,189 shares — an estimated $2.45M sold.

Nebula Research & Development first reported a position in ABBV in Q4 2023 and held it in 4 quarters. The position peaked at $4.1M in Q1 2025. 3,905 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

  • Nebula Research & Development reported no remaining AbbVie position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 13,189 AbbVie shares in Q3 2025, an estimated $2.45M.
  • Nebula Research & Development first reported a position in AbbVie in Q4 2023 and held it in 4 quarters.
  • Nebula Research & Development's AbbVie position peaked at $4.1M in Q1 2025.
  • 3,905 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.